OBJECTIVE: New screening guidelines recommend that human papillomavirus (HPV)-negative/atypical squamous cells of undetermined significance (ASC-US) results be considered as equivalent to HPV-negative/Pap-negative results, leading to rescreening in 5 years. However, despite ample data, the routine clinical performance of HPV testing of women with ASC-US has not been adequately documented. METHODS: We estimated 5-year risks of cervical intraepithelial neoplasia (CIN) 3+ and of cancer among 2 groups of women between 2003 and 2010 at Kaiser Permanente Northern California: 27,050 aged 30 to 64 years who underwent HPV and Pap cotesting and had an ASC-US Pap result and 12,209 aged 25 to 29 years who underwent HPV triage of ASC-US. RESULTS: Five-year risks of CIN 3+ and of cancer among women aged 30 to 64 years testing HPV-negative/ASC-US and among 923,152 women testing Pap-negative alone were similar although statistically distinguishable (CIN 3+, 0.43% vs 0.26%, p = .001; cancer, 0.050% vs 0.025%, p = .1). The increased risk of cancer after HPV-negative/ASC-US versus Pap-negative alone was confined to women aged 60 to 64 years (0.26% vs 0.035%, p = .3). Five-year risks of CIN 3+ and cancer among women with HPV-negative/ASC-US results were substantially higher than those among women testing HPV-negative/Pap-negative (CIN 3+, 0.43% vs 0.08%, p < .0001; cancer, 0.050% vs 0.011%, p = .003). For women aged 30 to 64 years testing HPV-positive/ASC-US, 5-year risks of CIN 3+ and cancer were slightly higher than those among 9,374 women with low-grade squamous intraepithelial lesion (LSIL) (CIN 3+, 6.8% vs 5.2%, p = .0007; cancer, 0.41% vs 0.16%, p = .04). Similar patterns were seen for women aged 25 to 29 years. CONCLUSIONS: Women with HPV-negative/ASC-US had a similar risk as women testing Pap-negative alone but had a higher risk than women testing HPV-negative/Pap-negative. Based upon the principle of "equal management of equal risks," our findings support the equal management of women with HPV-negative/ASC-US and those with Pap-negative alone, except for exiting women from screening because cancer risks at ages 60 to 64 years may be higher for women testing HPV-negative/ASC-US. Our findings also support managing HPV-positive/ASC-US and LSIL similarly.
OBJECTIVE: New screening guidelines recommend that human papillomavirus (HPV)-negative/atypical squamous cells of undetermined significance (ASC-US) results be considered as equivalent to HPV-negative/Pap-negative results, leading to rescreening in 5 years. However, despite ample data, the routine clinical performance of HPV testing of women with ASC-US has not been adequately documented. METHODS: We estimated 5-year risks of cervical intraepithelial neoplasia (CIN) 3+ and of cancer among 2 groups of women between 2003 and 2010 at Kaiser Permanente Northern California: 27,050 aged 30 to 64 years who underwent HPV and Pap cotesting and had an ASC-US Pap result and 12,209 aged 25 to 29 years who underwent HPV triage of ASC-US. RESULTS: Five-year risks of CIN 3+ and of cancer among women aged 30 to 64 years testing HPV-negative/ASC-US and among 923,152 women testing Pap-negative alone were similar although statistically distinguishable (CIN 3+, 0.43% vs 0.26%, p = .001; cancer, 0.050% vs 0.025%, p = .1). The increased risk of cancer after HPV-negative/ASC-US versus Pap-negative alone was confined to women aged 60 to 64 years (0.26% vs 0.035%, p = .3). Five-year risks of CIN 3+ and cancer among women with HPV-negative/ASC-US results were substantially higher than those among women testing HPV-negative/Pap-negative (CIN 3+, 0.43% vs 0.08%, p < .0001; cancer, 0.050% vs 0.011%, p = .003). For women aged 30 to 64 years testing HPV-positive/ASC-US, 5-year risks of CIN 3+ and cancer were slightly higher than those among 9,374 women with low-grade squamous intraepithelial lesion (LSIL) (CIN 3+, 6.8% vs 5.2%, p = .0007; cancer, 0.41% vs 0.16%, p = .04). Similar patterns were seen for women aged 25 to 29 years. CONCLUSIONS:Women with HPV-negative/ASC-US had a similar risk as women testing Pap-negative alone but had a higher risk than women testing HPV-negative/Pap-negative. Based upon the principle of "equal management of equal risks," our findings support the equal management of women with HPV-negative/ASC-US and those with Pap-negative alone, except for exiting women from screening because cancer risks at ages 60 to 64 years may be higher for women testing HPV-negative/ASC-US. Our findings also support managing HPV-positive/ASC-US and LSIL similarly.
Authors: Marc Arbyn; Christine Bergeron; Paul Klinkhamer; Pierre Martin-Hirsch; Albertus G Siebers; Johan Bulten Journal: Obstet Gynecol Date: 2008-01 Impact factor: 7.661
Authors: Hormuzd A Katki; Mark Schiffman; Philip E Castle; Barbara Fetterman; Nancy E Poitras; Thomas Lorey; Li C Cheung; Tina Raine-Bennett; Julia C Gage; Walter K Kinney Journal: J Low Genit Tract Dis Date: 2013-04 Impact factor: 1.925
Authors: Mark H Einstein; Mark G Martens; Francisco A R Garcia; Daron G Ferris; Amy L Mitchell; Stephen P Day; Marilyn C Olson Journal: Gynecol Oncol Date: 2010-05-21 Impact factor: 5.482
Authors: Mark H Stoler; Thomas C Wright; Abha Sharma; Raymond Apple; Karen Gutekunst; Teresa L Wright Journal: Am J Clin Pathol Date: 2011-03 Impact factor: 2.493
Authors: Marc Arbyn; Peter Sasieni; Chris J L M Meijer; Christine Clavel; George Koliopoulos; Joakim Dillner Journal: Vaccine Date: 2006-08-31 Impact factor: 3.641
Authors: Diane Solomon; Diane Davey; Robert Kurman; Ann Moriarty; Dennis O'Connor; Marianne Prey; Stephen Raab; Mark Sherman; David Wilbur; Thomas Wright; Nancy Young Journal: JAMA Date: 2002-04-24 Impact factor: 56.272
Authors: Albertus G Siebers; Paul J J M Klinkhamer; Johanna M M Grefte; Leon F A G Massuger; Judith E M Vedder; Angelique Beijers-Broos; Johan Bulten; Marc Arbyn Journal: JAMA Date: 2009-10-28 Impact factor: 56.272
Authors: Guglielmo Ronco; Jack Cuzick; Paola Pierotti; Maria Paola Cariaggi; Paolo Dalla Palma; Carlo Naldoni; Bruno Ghiringhello; Paolo Giorgi-Rossi; Daria Minucci; Franca Parisio; Ada Pojer; Maria Luisa Schiboni; Catia Sintoni; Manuel Zorzi; Nereo Segnan; Massimo Confortini Journal: BMJ Date: 2007-05-21
Authors: Hormuzd A Katki; Mark Schiffman; Philip E Castle; Barbara Fetterman; Nancy E Poitras; Thomas Lorey; Li C Cheung; Tina Raine-Bennett; Julia C Gage; Walter K Kinney Journal: J Low Genit Tract Dis Date: 2013-04 Impact factor: 1.925
Authors: Julia C Gage; William C Hunt; Mark Schiffman; Hormuzd A Katki; Li C Cheung; Jack Cuzick; Orrin Myers; Philip E Castle; Cosette M Wheeler Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-10-30 Impact factor: 4.254
Authors: Hilary A Robbins; Howard D Strickler; L Stewart Massad; Christopher B Pierce; Teresa M Darragh; Howard Minkoff; Marla J Keller; Margaret Fischl; Joel Palefsky; Lisa Flowers; Lisa Rahangdale; Joel Milam; Sadeep Shrestha; Christine Colie; Gypsyamber DʼSouza Journal: AIDS Date: 2017-04-24 Impact factor: 4.177
Authors: Sheila Weinmann; Andrew E Williams; Aruna Kamineni; Diana S M Buist; Erin E Masterson; Natasha K Stout; Azadeh Stark; Tyler R Ross; Christopher L Owens; Terry S Field; Chyke A Doubeni Journal: Cancer Date: 2015-05-18 Impact factor: 6.860
Authors: Hormuzd A Katki; Mark Schiffman; Philip E Castle; Barbara Fetterman; Nancy E Poitras; Thomas Lorey; Li C Cheung; Tina Raine-Bennett; Julia C Gage; Walter K Kinney Journal: J Low Genit Tract Dis Date: 2013-04 Impact factor: 1.925
Authors: Hormuzd A Katki; Mark Schiffman; Philip E Castle; Barbara Fetterman; Nancy E Poitras; Thomas Lorey; Li C Cheung; Tina Raine-Bennett; Julia C Gage; Walter K Kinney Journal: J Low Genit Tract Dis Date: 2013-04 Impact factor: 1.925